CytomX Therapeutics

www.cytomx.com

CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

Industrial Impact

O2 INVESTS IN MODULAR DEVICES, INC.

O2 Investment Partners ( | January 24, 2022

news image

O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases t...

Read More

Industrial Impact

C-LECTA ANNOUNCES THAT IT HAS REACHED AGREEMENT TO BE ACQUIRED BY KERRY GROUP

c-LEcta | February 16, 2022

news image

c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-...

Read More

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

news image

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More
news image

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More
news image

Industrial Impact

O2 INVESTS IN MODULAR DEVICES, INC.

O2 Investment Partners ( | January 24, 2022

O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases t...

Read More
news image

Industrial Impact

C-LECTA ANNOUNCES THAT IT HAS REACHED AGREEMENT TO BE ACQUIRED BY KERRY GROUP

c-LEcta | February 16, 2022

c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-...

Read More
news image

BOLT BIOTHERAPEUTICS RAISES $93.5 MILLION SERIES C FINANCING

Bolt Biotherapeutics | July 06, 2020

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer, today announced the closing of an oversubscribed $93.5 million Series C financing. Led by Sofinnova Investments, the Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us